

07 Sep 2020 |

Quick Listen: Scrip's Five Must-Know Things

by **Ian Haydock**

Join us for a quick audio roundup of five useful things to know from *Scrip's* recent coverage of developments in the global biopharmaceutical industry.

Take a brief audio tour around *Scrip's* Five Must-Know Things, in this episode covering major developments in the business week ended 4 September 2020.

In the spotlight this week are new trial results in the SGLT2 inhibitor and cardiovascular spaces, antibodies in development for COVID-19, and how the pandemic is affecting consumers' perceptions of healthcare.

Stories mentioned in this episode:

(Also see "[DAPA-CKD Data Put AstraZeneca's Farxiga Out Front](#)" - Scrip, 31 Aug, 2020.)

(Also see "[Heart Failure A Key Future Market For Jardiance?](#)" - Scrip, 2 Sep, 2020.)

(Also see "[As FDA Decision Nears, Novartis Highlights New Analysis Of Blockbuster Hopeful Inclisiran](#)" - Scrip, 1 Sep, 2020.)

(Also see "[Regeneron and Roche Await Data On Potential COVID-19 Blockbuster](#)" - Scrip, 3 Sep, 2020.)

(Also see "[Post-COVID-19 Consumer Preferences A Guide For Pharma Strategy](#)" - Scrip, 31 Aug, 2020.)

[Click here to explore this interactive content online](#) ✨